Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
expanded autologous adipose-derived stem cells (University Hospital, Toulouse)
- Development stage
- Unknown
- Lead developer
- CHU de Toulouse
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intramuscular
01
Overview
Expanded autologous adipose-derived stem cells (ASCs) is an investigational cell therapy developed by University Hospital, Toulouse for the treatment of non-revascularizable critical limb ischemia (CLI). The therapy involves the extraction of a patient's own adipose tissue, followed by the in vitro expansion of the mesenchymal stem/stromal cell population. These expanded cells are then delivered via multiple intramuscular injections into the ischemic limb. The mechanism of action is primarily paracrine, where the injected ASCs secrete a variety of angiogenic, anti-inflammatory, and anti-apoptotic factors that stimulate the formation of new blood vessels (angiogenesis) and promote tissue repair in the hypoxic environment. The safety and feasibility of this approach were evaluated in the ACellDREAM Phase I clinical trial, which showed improved wound healing and limb salvage in patients with no other revascularization options.
- Other names
- expanded autologous ASCsautologous adipose-derived stroma/stem cellsautologous adipose-derived stem cellsautologous ASCs
Beyond the preview
Go deeper on expanded autologous adipose-derived stem cells (University Hospital, Toulouse).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on expanded autologous adipose-derived stem cells (University Hospital, Toulouse).